Key result
Antecedent cancer in patients with Takotsubo syndrome was associated with a significantly increased risk of long-term all-cause mortality (HR 2.4) and cardiovascular mortality (HR 3.1).
Why the study?
There is increasing evidence of a nexus between Takotsubo syndrome and underlying malignancies, prompting evaluation of interactions between antecedent cancer and early and late clinical course.
Does antecedent cancer increase the risk of in-hospital complications and long-term mortality in patients with Takotsubo syndrome?
Cohort (n=346)
Yes
Does antecedent cancer increase the risk of in-hospital complications and long-term mortality in patients with Takotsubo syndrome?
Hazard Ratio: 2.4
p-value: p=0.0001
Antecedent cancer in patients with Takotsubo syndrome is associated with greater initial clinical severity and substantially higher long-term cardiovascular and all-cause mortality.
Antecedent cancer signals higher TTS severity and long-term mortality; leaves open whether screening or therapy alters outcomes.
Background Takotsubo syndrome (TTS), primarily an acute myocardial inflammatory condition engendered by catecholamine exposure, is associated with similar long-term mortality rates to those of patients with acute myocardial infarction. However, there is increasing evidence of a nexus between TTS and underlying malignancies:- many patients have antecedent cancer (A/Ca), while incremental risk of late cancer-related death has also been reported. Purpose To evaluate potential interactions between A/Ca among TTS patients and both early and late clinical course. Methods Three hundred forty-six consecutive TTS patients [aged 69 ± 13 (SD) years, males: 8.2%] were prospectively followed up for a median duration of 4.1 (IQR 2.2–6.4) years. Associations between A/Ca and severity of acute attacks, in-hospital complications and long-term death rates were sought utilising univariate analyses followed by multiple logistic regression analysis. Results A/Ca (present in 16.8% of patients) was associated with (i) greater elevation of hs-CRP and NT-proBNP concentrations (p = 0.01 and 0.04, respectively), (ii) more complicated in-hospital clinical course, with major adverse cardiac events (MACE) in 30.9% of patients, compared to 18.2% in non-A/Ca patients (p = 0.04). Long-term all-cause mortality rate was also greater [hazard ratio (HR) = 2.4, p = 0.0001] in A/Ca patients, with an excess cardiovascular (CVS) fatality rate (HR = 3.1, p = 0.001). On multivariate analysis, male gender, peak plasma concentrations of normetanephrine and hs-CRP, early arrhythmias and development of shock, but not A/Ca per se, were all independently associated with increased long-term mortality rate. Furthermore, patients discharged on β-adrenoceptor antagonists (βBl) or angiotensin converting enzyme inhibitors/ angiotensin receptor blockers (ACEi/ARB) had lower long-term mortality rates (β = − 0.2, p = 0.01; β = − 0.14, p = 0.05, respectively). Conclusions (1) A/Ca is associated with greater clinical severity of initial TTS attacks and substantially greater long-term CVS-related as well as all-cause mortality. (2) Post-discharge therapy with either βBl or ACEi/ARB is associated with reductions in long-term mortality rates. Overall, the current data suggest operation of substantial interactions between neoplasia and TTS, both at the level of pathogenesis and of outcomes.
No takes yet. Share an insight, caveat, or question.
Nguyen et al. (2019) conducted a cohort in Takotsubo syndrome (n=346). Antecedent cancer vs. No antecedent cancer was evaluated on Long-term all-cause mortality (HR 2.4, p=0.0001). Antecedent cancer in patients with Takotsubo syndrome was associated with a significantly increased risk of long-term all-cause mortality (HR 2.4) and cardiovascular mortality (HR 3.1).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: